One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made an interesting announcement. The healthcare company said that it will now offer branded Zepbound, Eli Lilly’s (NYSE: LLY) blockbuster weight loss drug. Zepbound is the most effective weight loss drug that has been approved by the Food and Drug Administration (FDA).
Studies have found that patients lose around 21% of their weight on average at the highest dose. This is significantly more than the 15% seen by Novo Nordisk's A/S (NYSE: NVO) Wegovy. Hims will also offer liraglutide, another weight loss treatment. Shares of Hims rose 5% after this announcement, indicating that markets saw it as a positive development.
